middle.news
How LTR Pharma’s Intranasal ED Sprays Are Poised to Disrupt Global Markets
3:48am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How LTR Pharma’s Intranasal ED Sprays Are Poised to Disrupt Global Markets
3:48am on Saturday 30th of August, 2025 AEST
Key Points
First patient treated with SPONTAN under Australia’s Special Access Scheme
Strategic co-development agreement with Aptar Pharma for FDA regulatory support
Expanded national distribution agreements with Symbion and TerryWhite Chemmart
Launch of new intranasal products ROXUS and OROFLOW targeting large global markets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
LTP
OPEN ARTICLE